Rachel Haurwitz

President and Chief Executive Officer, Caribou Biosciences

Rachel has a research background in CRISPR-Cas biology and holds several patents covering CRISPR-derived technologies. She co-founded Caribou in 2012 and Intellia Therapeutics in 2014, both of which are developing genome editing therapies.

Part of the Power List 2019

Breakthroughs at the bench, novel technologies and groundbreaking policies and regulation have helped the pharma industry grow from strength to strength. After months of collating reader nominations and judging overseen by a panel of industry experts, we proudly present The Medicine Maker 2019 Power List, featuring 100 of the industry’s pioneers across four categories: Industry Influencers, Business Captains, Masters of the Bench, and Champions of Change.

Go to The Power List 2019